Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
A6NHQ2
UPID:
FBLL1_HUMAN
Alternative names:
Protein-glutamine methyltransferase
Alternative UPACC:
A6NHQ2; R4GMW7
Background:
The rRNA/tRNA 2'-O-methyltransferase fibrillarin-like protein 1, also known as Protein-glutamine methyltransferase, plays a crucial role in cellular function through its S-adenosyl-L-methionine-dependent methyltransferase activity. It is instrumental in pre-rRNA processing, catalyzing site-specific 2'-hydroxyl methylation of ribose moieties in pre-ribosomal RNA, and also serves as a protein methyltransferase by mediating methylation of glutamine residues.
Therapeutic significance:
Understanding the role of rRNA/tRNA 2'-O-methyltransferase fibrillarin-like protein 1 could open doors to potential therapeutic strategies.